Cellect Biotechnology: Surges on positive recommendation from safety review committee

Quoin Pharmaceuticals

12/08/2019 13:31

**  U.S.-listed shares of Israel-based stem cell therapy
developer  APOP.O  up 44% at 60 cents premarket 
    ** Says received positive recommendation for its early stage
stem-cell therapy study, which was reviewed by a safety review
committee urn:newsml:reuters.com:*:nPn7CN9Gqa
    ** Expects to complete the patient recruitment by the end of
2019 and release data during the first half of 2020 - APOP
    ** We are getting closer to realizing our plans to initiate
our first trial in the U.S. - CEO Shai Yarkoni
    ** Stock among biggest pct gainers among U.S. exchanges
    ** Up to Friday's close, stock down ~80% this year

 (Reporting by Aakash Jagadeesh Babu in Bengaluru)
 ((Aakash.B@thomsonreuters.com; within the U.S. +16462238780,
outside the U.S. +91  80 67491576; Twitter: @JagadeeshAakash;))